Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Stomach is the most affected site. Clinical manifestation is erratic depending on the locations, size, histological type and stage. Confirmed diagnosis of GISTs bases on immunohistochemical study. Most of GISTs are histopositive for the tyrosine kinase KIT receptor (also known as CD 117). CT scan is the imaging modality of choice in the detection of tumors, evaluation of tumor expansion or seeding, treatment planning and surveillance of recurrence. Complete surgical resection of the tumor remains the first line treatment. Imatinib mesylate, an oral tyrosine kinase inhibitor, has dramatically changed GIST therapy.